Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T151742
- Development stage
- Unknown
- Lead developer
- West Virginia University
01
Overview
T151742: sourced facts only. name: "We identified T151742 as an ERO1α inhibitor that was approximately 2-fold more potent compared to the previously published ERO1α inhibitor EN460." [DOI:10.1158/1538-7445.am2022-3993]; target: "We identified T151742 as an ERO1α inhibitor that was approximately 2-fold more potent compared to the previously published ERO1α inhibitor EN460." [DOI:10.1158/1538-7445.am2022-3993]; developer: "1West Virginia University, Morgantown, WV." [DOI:10.1158/1538-7445.am2022-3993]; stage: "Finally, treatment of PC9 and HCC4006 cells with T151742 in combination with Osimertinib was synergistic in vitro." [DOI:10.1158/1538-7445.am2022-3993]
02
Targets
ERO1A (Endoplasmic reticulum oxidoreductin-1 alpha)
Beyond the preview
Go deeper on T151742.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T151742.